Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)

BACKGROUND: Many patients with Cushing’s disease (CD) require long-term medical therapy to control their hypercortisolism. In the core phase of a Phase II study (LINC 2; NCT01331239), osilodrostat normalized mean urinary free cortisol (mUFC) in 78.9% of patients with CD. Here, we report long-term ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleseriu, Maria, Biller, Beverly M. K., Bertherat, Jérôme, Young, Jacques, Hatipoglu, Betul, Arnaldi, Giorgio, O’Connell, Paul, Izquierdo, Miguel, Pedroncelli, Alberto M., Pivonello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675663/
https://www.ncbi.nlm.nih.gov/pubmed/36219274
http://dx.doi.org/10.1007/s11102-022-01280-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675663/
https://www.ncbi.nlm.nih.gov/pubmed/36219274
http://dx.doi.org/10.1007/s11102-022-01280-6

Ejemplares similares